Pulished Date August, 2019
ID: 160
Share on
Share on

Asia Pacific Cancer Monoclonal Antibodies Market Research Report – Segmented By Application, By Type, By Conjugated Cancer Therapies & By Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Global Industry Analysis, Size, Share, Growth, Trends, Forecast (2019-2024)

Pulished: August, 2019
ID: 160
Pages: 145

APAC Cancer Monoclonal Antibodies Market Size & Growth (2019 - 2024)

The size of the Cancer Monoclonal Antibodies Market in the Asia Pacific was valued at USD 5.94 billion in 2018 and is forecasted to be a USD 10.95 Billion market by 2023 with a tremendous growth rate of 13%.

Cancer is the leading cause of death currently across the globe. It starts with a single cell genetically transforming a normal cell into a tumour and is spread gradually to the other cells. The dramatic increases in the number of cancer cases have prompted many pharmaceutical companies to invest in monoclonal antibodies. The practice for curing cancer currently includes the usage of drugs and chemotherapy which have adverse side effects. This persuades the usage of Monoclonal antibodies.

The drastic increase in the people affected by cancer prompted many pharmaceutical firms to invest in monoclonal antibodies. Rise in investment in R&D of genomic studies, technological innovations in target gene selection and genetic sequencing, monoclonal antibodies ability to target only specific cells, having no side effects compared to its counterparts are the primary drivers for the market. With the increased occurrence of cancer, the market is expected to grow significantly in the next 5 years having the presence of highly strong products in the pipeline. There are also few restraints for its market entry like high cost, stringent guidelines, long durations required for R&D, clinical trials.

Recent years have seen the emergence of the monoclonal antibodies market, offering less toxic and highly efficient therapeutics alternatives. The antibody agents are used to cure a wide array of diseases, especially cancer, autoimmune and inflammatory diseases. They are mono-specific antibodies having identical immune cells that are clone to the single parent cells and are directed to a specific target cell. This customizable feature of the antibodies due to its specific nature can play a critical role in eliminating the cancer cell while sparing the healthy cells. Monoclonal antibodies are more effective in treating cancer than their counterparts like drugs or chemotherapy owing to their adverse side effects.

This research report segmented and sub-segmented into the following categories:

  • By Application: Liver, Breast, Blood, Brain, Hodgkin’s And Non-Hodgkin’s Lymphoma, Colorectal, Leukaemia, and Others
  • By Type: Murine Antibodies, Chimeric & Humanised Antibodies, Fully Humanized Antibodies
  • By Conjugated Cancer Therapies: Immunoliposome, Radioimmunotherapy, ADEPT, Immunocytokines, Others
  • By Country: India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC

Leading companies in this market

Prominent companies dominating the APAC Cancer Monoclonal Antibodies Market profiled in this report are Amgen, Genmab, Briston Myers Squibb, Glaxosmithkline, Eli Lilly, Roche, Immunogen, Seattle Genetics, Novartis & Spectrum Pharmaceuticals.

  1. Introduction

                1.1 Market Definition    

                1.2 Study Deliverables  

                1.3 Base Currency, Base Year and Forecast Periods          

                1.4 General Study Assumptions

  1. Research Methodology

                2.1 Introduction               

                2.2 Research Phases      

                                2.2.1 Secondary Research

                                2.2.2 Primary Research

                                2.2.3 Econometric Modelling

                                2.2.4 Expert Validation

                2.3 Analysis Design         

                2.4 Study Timeline          

  1. Overview

                3.1 Executive Summary

                3.2 Key Inferences         

                3.3 New Developments               

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers          

                4.2 Market Restraints    

                4.3 Key Challenges         

                4.4 Current Opportunities in the Market              

  1. Market Segmentation

                5.1 By Application           

                                5.1.1 Liver

                                5.1.2 Breast

                                5.1.3 Brain

                                5.1.4 Blood

                                5.1.5 Hodgkins and Non-Hodgkins lymphoma

                                5.1.6 Colorectal

                                5.1.7 Leukaemia

                                5.1.8 Others

                5.2 By Type        

                                5.2.1 Murine Antibodies

                                5.2.2 Chimeric and Humanised Antibodies

                                5.2.3 Fully Humanized Antibodies

                5.3 Conjugate Cancer Therapies               

                                5.3.1 Immunoliposome

                                5.3.2 Radioimmunotherapy

                                5.3.3 ADEPT

                                5.3.4 Immunocytokines

                                5.3.5 Others

  1. Geographical Analysis

                6.1 Introduction               

                6.2 China             

                6.3 India              

                6.4 Japan            

                6.5 South Korea               

  1. Strategic Analysis

                7.1 PESTLE analysis         

                                7.1.1 Political

                                7.1.2 Economic

                                7.1.3 Social

                                7.1.4 Technological

                                7.1.5 Legal

                                7.1.6 Environmental

                7.2 Porter’s Five analysis              

                                7.2.1 Bargaining Power of Suppliers

                                7.2.2 Bargaining Power of Consumers

                                7.2.3 Threat of New Entrants

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry

  1. Market Leaders' Analysis

                8.1 Roche

                                8.1.1 Overview

                                8.1.2 Product Analysis

                                8.1.3 Strategic Evaluation and Operations

                                8.1.4 Financial analysis

                                8.1.5 Legal issues

                                8.1.6 Recent Developments

                                8.1.7 SWOT analysis

                                8.1.8 Analyst View

                8.2 Amgen

                8.3 Genmab

                8.4 Glaxosmithkline

                8.5 Bristol Meyer Squibb

                8.6 Eli Lilly

                8.7 Immunogen

                8.8 Novartis

                8.9 Seattle Genetics

                8.10 Spectrum Pharmaceuticals

  1. Competitive Landscape

                9.1 Market share analysis            

                9.2 Merger and Acquisition Analysis       

                9.3 Agreements, collaborations and Joint Ventures         

                9.4 New Product Launches         

  1. Expert Opinions

                10.1 Market Outlook     

                10.2 Investment Opportunities 

     Appendix                           

  1. List of Tables
  2. List of Figures
  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Cancer Monoclonal Antibodies Market By Region, From 2019-2024 ( USD Million )
  2. Asia-Pacific Cancer Monoclonal Antibodies Market By Application, From 2019-2024 ( USD Million )
  3. Asia-Pacific Liver Market By Region, From 2019-2024 ( USD Million )
  4. Asia-Pacific Breast Market By Region, From 2019-2024 ( USD Million )
  5. Asia-Pacific Brain Market By Region, From 2019-2024 ( USD Million )
  6. Asia-Pacific Blood Market By Region, From 2019-2024 ( USD Million )
  7. Asia-Pacific Hodgkins and Non-Hodgkins lymphoma Market By Region, From 2019-2024 ( USD Million )
  8. Asia-Pacific Colorectal Market By Region, From 2019-2024 ( USD Million )
  9. Asia-Pacific Leukaemia Market By Region, From 2019-2024 ( USD Million )
  10. Asia-Pacific Others Market By Region, From 2019-2024 ( USD Million )
  11. Asia-Pacific Cancer Monoclonal Antibodies Market By Type, From 2019-2024 ( USD Million )
  12. Asia-Pacific Murine Antibodies Market By Region, From 2019-2024 ( USD Million )
  13. Asia-Pacific Chimeric and Humanised Antibodies Market By Region, From 2019-2024 ( USD Million )
  14. Asia-Pacific Fully Humanized Antibodies Market By Region, From 2019-2024 ( USD Million )
  15. Asia-Pacific Cancer Monoclonal Antibodies Market By Conjugate Cancer Therapies, From 2019-2024 ( USD Million )
  16. Asia-Pacific Immunoliposome Market By Region, From 2019-2024 ( USD Million )
  17. Asia-Pacific Radioimmunotherapy Market By Region, From 2019-2024 ( USD Million )
  18. Asia-Pacific ADEPT Market By Region, From 2019-2024 ( USD Million )
  19. Asia-Pacific Immunocytokines Market By Region, From 2019-2024 ( USD Million )
  20. Asia-Pacific Others Market By Region, From 2019-2024 ( USD Million )
  21. Cancer Monoclonal Antibodies Market By Application, From 2019-2024 ( USD Million )
  22. Liver Market By Region, From 2019-2024 ( USD Million )
  23. Breast Market By Region, From 2019-2024 ( USD Million )
  24. Brain Market By Region, From 2019-2024 ( USD Million )
  25. Blood Market By Region, From 2019-2024 ( USD Million )
  26. Hodgkins and Non-Hodgkins lymphoma Market By Region, From 2019-2024 ( USD Million )
  27. Colorectal Market By Region, From 2019-2024 ( USD Million )
  28. Leukaemia Market By Region, From 2019-2024 ( USD Million )
  29. Others Market By Region, From 2019-2024 ( USD Million )
  30. China Cancer Monoclonal Antibodies Market By Application, From 2019-2024 ( USD Million )
  31. China Cancer Monoclonal Antibodies Market By Type, From 2019-2024 ( USD Million )
  32. China Cancer Monoclonal Antibodies Market By Conjugate Cancer Therapies, From 2019-2024 ( USD Million )
  33. India Cancer Monoclonal Antibodies Market By Application, From 2019-2024 ( USD Million )
  34. India Cancer Monoclonal Antibodies Market By Type, From 2019-2024 ( USD Million )
  35. India Cancer Monoclonal Antibodies Market By Conjugate Cancer Therapies, From 2019-2024 ( USD Million )
  36. Japan Cancer Monoclonal Antibodies Market By Application, From 2019-2024 ( USD Million )
  37. Japan Cancer Monoclonal Antibodies Market By Type, From 2019-2024 ( USD Million )
  38. Japan Cancer Monoclonal Antibodies Market By Conjugate Cancer Therapies, From 2019-2024 ( USD Million )
  39. South Korea Cancer Monoclonal Antibodies Market By Application, From 2019-2024 ( USD Million )
  40. South Korea Cancer Monoclonal Antibodies Market By Type, From 2019-2024 ( USD Million )
  41. South Korea Cancer Monoclonal Antibodies Market By Conjugate Cancer Therapies, From 2019-2024 ( USD Million )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample